BTG
London, United Kingdom
London, United Kingdom

BTG plc, a public limited company is an international specialty pharmaceuticals company that is developing and commercialising products targeting critical care, cancer, neurological and other disorders. The company is also seeking to acquire new products to develop and market to hospital specialists, and is building a sustainable business financed by revenues from sales of its critical care products and from royalties and milestone payments on partnered products. Wikipedia.


Time filter

Source Type

Patent
Btg | Date: 2016-10-13

A method is provided for treating a subject in need of medication as an adjunct to elective surgery, comprising administration of a ketogenic material sufficient to produce a physiologically acceptable ketosis in the patient. Preferably the surgery is selected from the groups consisting of removal or section of tumours, removal of redundant organs such as lymph nodes and appendix, open heart surgery, cosmetic surgery, joint and bone surgery.


Patent
Btg | Date: 2015-10-06

A method is described for providing acute symptomatic relief to a subject with Parkinsons Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit in such neurological disorders. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM.


Grant
Agency: European Commission | Branch: H2020 | Program: RIA | Phase: LCE-02-2015 | Award Amount: 5.47M | Year: 2016

The overall objective of Residue2Heat is to enable the utilization of sustainable, ash rich biomass and residues in residential heating applications (20-200 kWth) to provide sustainable heat at a competitive price. In this concept, various 2nd generation agricultural, and forestry residue streams are converted into a liquid energy carrier near the biomass origin at an economic viable scale of 15-30 MWth using the fast pyrolysis process. Subsequently, the fast pyrolysis bio-oil (FPBO) is distributed to a large number of residential end-users. The FPBO should fulfill at least the draft CEN-specification for replacement of domestic heating oil and comply with REACH regulation. Additional quality control aspects for this application include the removal of extractives and solids from the FPBO. Ash is recovered from the fast pyrolysis process as a separate stream, and recycling and/or re-use will be evaluated in detail. Existing high efficient, condensing boilers are used as starting point in the project, as well as a proven, low emission blue-flame type burner. Within Residue2Heat technical development work is performed on the modification of such systems to enable FPBO as fuel. The emission control and energy efficiency of the heating systems are optimized by dedicated modeling of FPBO atomization and combustion kinetics, supported by single droplet combustion tests and spray characterization. This route benefits from the flexible nature of the fast pyrolysis process, allowing the use of various lignocellulosic biomass streams, but also by using modified residential heating systems for which manufacturing capabilities, market development and product distribution are already in place. Dedicated tasks are included to assess the environmental and social impacts, risks analysis and public acceptance. Additionally, business and market assessment activities are performed including specific issues on health and safety relevant to FPBO-fuelled residential boilers.


Patent
Btg | Date: 2015-01-26

A method is described for providing acute symptomatic relief to a subject with Parkinsons Disease (PD) or other CNS disorders resulting from dopamine deficiency in the brain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide therapeutic benefit in such neurological disorders. Preferred materials produce a ketosis is such that the total concentration of acetoacetate and (R)-3-hydroxybutyrate in the blood of the subject is raised to between 0.1 and 30 mM.


Patent
Btg | Date: 2015-03-17

A packaging unit or a container for transport and/or storage of items that require orientation control, comprising an outer housing element and an inner retaining element, the retaining element being held within the housing element and capable of moving independently of the housing element about at least one axis the retaining element being adapted to retain the item and comprising a means for biasing the orientation of the inner retaining element with respect to a fixed external orientation.


A salt of a compound of formula (I) may be made with methanesulfonic acid. The salt and salts with other acids may be prepared by recovering from methyl tert-butyl ether (MTBE).


Patent
Btg | Date: 2015-06-08

The present invention provides a surgical clamp comprising a temperature sensitive shape memory material, the clamp capable of taking up a first form in which the clamp (6) is shaped to at least partially encircle a tubular structure (14); a second form shaped to substantially completely encircle the tubular structure (14) and constrict it, the clamp changing from the first form to the second form above the transition temperature of the shape memory material; and a third form derived from the first form by resilient deformation of the clamp in its first form. The present invention also provides applicators for delivering the clamps and kits comprising the clamps.


Patent
Btg | Date: 2016-06-27

Apparatus, e.g. a syringe, for dispensing foam includes means for ensuring that only foam of adequate quality is dispensed. In use, the syringe may be filled from a pressurised canister which generates foam e.g. for therapeutic use in treating varicose veins. An initial quantity of foam dispensed from the canister may be of inadequate quality in which case it should not be used: the syringe includes means to ensure that this initial quantity of foam is diverted to a waste port or to an internal waste chamber e.g. located in the syringe plunger. Foam dispensed after the initial quantity of poor quality foam is stored in the main barrel of the syringe ready for administration to a patient in need of treatment.


Patent
Btg | Date: 2015-02-24

The invention herein disclosed is related to epitopes useful in methods of diagnosing, treating, and preventing coeliac disease. Therapeutic compositions which comprise at least one epitope are provided.


Patent
Btg | Date: 2015-10-08

Apparatus, e.g. a syringe, for dispensing foam includes means for ensuring that only foam of adequate quality is dispensed. In use, the syringe may be filled from a pressurised canister which generates foam e.g. for therapeutic use in treating varicose veins. An initial quantity of foam dispensed from the canister may be of inadequate quality in which case it should not be used: the syringe includes means to ensure that this initial quantity of foam is diverted to a waste port or to an internal waste chamber e.g. located in the syringe plunger. Foam dispensed after the initial quantity of poor quality foam is stored in the main barrel of the syringe ready for administration to a patient in need of treatment.

Loading BTG collaborators
Loading BTG collaborators